

1 **The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and**
2 **asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort**
3 **study using the UK Obstetric Surveillance System (UKOSS)**

4

5 Covid-19 in pregnancy

6

7 Nicola Vousden^{1,2} PhD, Kathryn Bunch MA¹, Edward Morris MD³, Nigel Simpson MBChB⁴, Christopher
8 Gale PhD⁵, Patrick O'Brien MBBCh⁶, Maria Quigley MSc¹, Peter Brocklehurst MSc⁷
9 Jennifer J Kurinczuk MD¹, Marian Knight DPhil¹

10

11 ¹National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of
12 Oxford, UK

13 ²School of Population Health & Environmental Sciences, King's College London, UK

14 ³Royal College of Obstetricians and Gynaecologists, London, UK

15 ⁴Department of Women's and Children's Health, School of Medicine, University of Leeds, UK

16 ⁵Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London,
17 UK

18 ⁶Institute for Women's Health, University College London, London, UK

19 ⁷Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, UK

20

21 Corresponding author:

22 Marian Knight, National Perinatal Epidemiology Unit, Nuffield Department of Population Health,
23 University of Oxford, Old Rd Campus, Oxford, OX3 7LF, UK

24 Tel: 01865 289727 Email: marian.knight@npeu.ox.ac.uk

25

26 Non-standard abbreviations:

27 Royal College of Obstetricians and Gynaecologists - RCOG

28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 **ABSTRACT**

30 **Background:**

31 Evidence on risk factors, incidence and impact of SARS-CoV-2 infection in pregnant mothers and their
32 babies has rapidly expanded but there is a lack of population level data to inform accurate incidence
33 rates and unbiased descriptions of characteristics and outcomes. The primary aim of this study was to
34 describe the incidence, characteristics and outcomes of hospitalized pregnant women with
35 symptomatic and asymptomatic SARS-CoV-2 in the UK compared to pregnant women without SARS-
36 CoV-2 in order to inform future clinical guidance and management.

37 **Methods and Findings:**

38 We conducted a national, prospective cohort study of all hospitalized pregnant women with
39 confirmed SARS-CoV-2 from 1st March 2020 to 31st August 2020 using the UK Obstetric Surveillance
40 System (UKOSS) across all 194 hospitals in the UK with a consultant-led maternity unit. Incidence was
41 estimated using the latest national maternity data. Overall, 1148 hospitalized women had confirmed
42 SARS-CoV-2 in pregnancy, 63% of which were symptomatic. Therefore, the estimated incidence of
43 hospitalization with symptomatic SARS-CoV-2 was 2.0 per 1000 maternities (95% CI 1.9-2.2) and for
44 asymptomatic SARS-CoV-2 was 1.2 per 1000 maternities (95% CI 1.1-1.4). Compared to pregnant
45 women without SARS-CoV-2, women hospitalized with symptomatic SARS-CoV-2 were more likely to
46 be overweight or obese (adjusted OR 1.86, 95% CI 1.39-2.48 and aOR 2.07, 95% CI 1.53-2.29
47 respectively), to be of Black, Asian or Other minority ethnic group (aOR 6.24, 95% CI 3.93-9.90, aOR
48 4.36, 95% CI 3.19-5.95 and aOR 12.95, 95% CI 4.93-34.01 respectively), and to have a relevant medical
49 comorbidity (aOR 1.83, 95% CI 1.32-2.54). Compared to pregnant women without SARS-CoV-2,
50 hospitalized pregnant women with symptomatic SARS-CoV-2 were more likely to be admitted to
51 intensive care (aOR 57.67, 95% CI 7.80-426.70) but the absolute risk of poor outcomes was low.
52 Cesarean births and neonatal unit admission were increased regardless of symptom status
53 (symptomatic aOR 2.60, 95% CI 1.97-3.42 and aOR 3.08, 95% CI 1.99-4.77 respectively; asymptomatic
54 aOR 2.02, 95% CI 1.52-2.70 and aOR 1.84, 95% 1.12-3.03 respectively). Iatrogenic preterm births were

55 more common in women with symptomatic SARS-CoV-2 (aOR 11.43, 95% CI 5.07-25.75). The risks of
56 stillbirth or neonatal death were not significantly increased, regardless of symptom status but
57 numbers were small. The limitations of this study include the restriction to women hospitalized with
58 SARS-CoV-2, who may by nature of their admission have been at greater risk of adverse outcome.

59

60 **Conclusions:**

61 We have identified factors that increase the risk of symptomatic and asymptomatic SARS-CoV-2 in
62 pregnancy. The increased risks of cesarean and iatrogenic preterm birth provide clear evidence of the
63 indirect impact of SARS-CoV-2 on mothers and maternity care in high income settings. Clinicians can
64 be reassured that the majority of women do not experience severe complications of SARS-CoV-2 in
65 pregnancy and women with mild disease can be discharged to continue their pregnancy safely.

66

67

68 INTRODUCTION

69

70 In March 2020 the World Health Organization declared a global pandemic of novel coronavirus
71 infection (SARS-CoV-2)[1]. Evidence about risk factors, incidence and impact of SARS-CoV-2 infection
72 in pregnant mothers and their babies has rapidly expanded and is vital to planning guidance and policy.
73 The World Health Organization's (WHO) living systematic review concluded that SARS-CoV-2 infection
74 was associated with increased risk of admission to intensive care for the mother and increased risk of
75 preterm birth and admission to neonatal care for the infant [2]. Women with pre-existing medical
76 comorbidities, older age, high body mass index (BMI) and women of Black, Asian and minority ethnic
77 groups have been reported to be at increased risk of hospitalization[3] or severe outcome [2].
78 However, the majority of studies to date are case reports, case series and institutional or registry non-
79 population-based cohort studies and there is a lack of population-level data to inform accurate
80 incidence rates and unbiased descriptions of characteristics and outcomes.

81

82 Clinical practice around testing for SARS-CoV-2 among pregnant women in the UK has changed since
83 the start of the pandemic, when predominantly only those with symptoms were tested. Routine
84 screening of all obstetric admissions was recommended by the Royal College of Obstetricians and
85 Gynaecologists (RCOG) on 29th May 2020 [4] and therefore the UK's obstetric population is unique in
86 that virtually all were tested thereafter, typically at the time of giving birth. The WHO systematic
87 review reported from 11 small observational studies (n=162 women that had universal screening) and
88 suggested that a high proportion of women who tested positive were asymptomatic (74%, 95% CI
89 51%-93%) [2]. Other reports have varied[5, 6], with between 79% (from a total of 55 women)[7] to
90 100% (from a total of 17 women) [8] of those that tested positive on universal screening being
91 asymptomatic. However, these studies were small and were undertaken in single hospitals or regions.
92 No published studies to date have explored the proportion of symptomatic versus asymptomatic
93 SARS-CoV-2 in pregnancy at the population level since universal screening was introduced.

94

95 The primary aim of this study was to describe the incidence, characteristics and outcomes of
96 hospitalized pregnant women with symptomatic and asymptomatic SARS-CoV-2 in the UK compared
97 to women without SARS-CoV-2, in order to inform ongoing guidance and management. The second
98 aim was to describe characteristics and outcomes in women with symptomatic SARS-CoV-2 compared
99 to those who remained asymptomatic.

100

101 **METHODS**

102

103 This on-going national, prospective observational cohort study was conducted using the UK Obstetric
104 Surveillance System (UKOSS) [9]. UKOSS is a research platform that was established in 2005 to collect
105 national population-based information about specific severe pregnancy complications. All 194
106 hospitals in the UK with a consultant-led maternity unit participate, and thus the mechanism to collect
107 comprehensive information about women hospitalized with SARS-CoV-2 in pregnancy was already in
108 place at the start of the pandemic. Nominated reporting clinicians were asked to notify all pregnant
109 women admitted to their hospital with confirmed SARS-CoV-2. The process was enabled by research
110 midwives and nurses from the UK's National Institute of Health Research Clinical Research Network
111 following the study's adoption as an urgent public health priority study [10]. To check for
112 completeness, a monthly reporting email was sent in addition to receipt of live reports, and zero
113 reports were confirmed. Following notification of a case, clinicians completed an electronic data
114 collection form containing anonymized details of women's demographics, management and birth and
115 perinatal outcomes. Reporters who had notified a case but not returned data were contacted by email
116 at one, two and three weeks after notification. This analysis reports characteristics and outcomes of
117 women who were hospitalized from 1st March 2020 to 31st August 2020. Hospital admission was
118 defined as a hospital stay of 24 hours or longer for any cause, or admission of any duration to give
119 birth. Women were taken as confirmed SARS-CoV-2 if they were hospitalized during pregnancy or
120 within two days of giving birth and had a positive test during or within seven days of admission, or

121 they were symptomatic and had evidence of pneumonia on imaging which was typical of SARS-CoV-
122 2. Women were excluded if they did not meet this case definition (n=294).

123

124 For each woman included, characteristics were described: body mass index, age, ethnicity, pregnancy
125 history and relevant pre-existing comorbidities, which were identified based on current NHS guidance
126 (Table S1)[11]). Details of pregnancy outcome including admission to intensive care, evidence of
127 pneumonia on imaging, pre-eclampsia and mode and indication for birth were described as well as
128 infant outcomes including gestation at birth, stillbirth, live birth, admission to neonatal intensive care,
129 neonatal death and neonatal testing for SARS-CoV-2. Information on women who died, or who had
130 consequent stillbirths or neonatal deaths, was cross-checked with data from the MBRRACE-UK
131 collaboration, the organization responsible for maternal and perinatal death surveillance in the UK
132 [12]. If any women were identified through these sources who had not been identified for this study,
133 the nominated UKOSS clinician in the relevant hospital was contacted and asked to complete a data
134 collection form.

135

136 Women with any symptoms of SARS-CoV-2 (fever, cough, sore throat, breathlessness, headache,
137 fatigue, limb or joint pain, vomiting, rhinorrhea, diarrhea, anosmia, or SARS CoV-2 pneumonia on
138 imaging) that were admitted to hospital were compared to a historical comparison cohort of
139 uninfected women. The historical comparison cohort were obtained from a previous study of seasonal
140 influenza in pregnancy, where the two women giving birth immediately prior to any woman
141 hospitalized with confirmed influenza between 1st November 2017 and 30th October 2018 were
142 identified [13]. A historical cohort was used to ensure there was no possibility that comparison women
143 had asymptomatic or minimally symptomatic SARS-CoV-2 infection. Women who tested positive
144 during routine screening at the time of hospital admission with no symptoms at any point were also
145 compared to this historical comparison group. A sub-analysis compared women admitted to hospital
146 with symptomatic SARS-CoV-2 and women found to have asymptomatic SARS-CoV-2.

147

148 **Study registration**

149 The study is registered with ISRCTN, number 40092247, and is still open to case notification. The study
150 protocol is available at [https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-](https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-pregnancy)
151 [pregnancy](https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-pregnancy).

152

153 **Role of the funding source**

154 The funder played no role in study design; in the collection, analysis, and interpretation of data; in the
155 writing of the report; nor the decision to submit the paper for publication. The corresponding author
156 (MK) had full access to all the data in the study and had final responsibility for the decision to submit
157 for publication.

158

159 **Ethics and consent**

160 This study was approved by the HRA NRES Committee East Midlands – Nottingham 1
161 (Ref. Number: 12/EM/0365).

162

163 **Statistical methods and analysis**

164 Statistical analyses were performed using STATA version 15 (Statacorp, TX, USA). Numbers and
165 proportions are presented with 95% confidence intervals. Where data were missing, proportions are
166 presented out of cases known. Odds ratios (ORs) with 95% confidence intervals (CI) were estimated
167 using unconditional logistic regression. Exploratory analysis, using a hierarchical stepwise forward
168 selection procedure to add additional variables associated with the outcome in the univariable
169 analysis with subsequent likelihood ratio testing, was used to identify any potential confounders or
170 mediators for each analysis (P -value <0.05 considered significant for inclusion in the model).
171 Continuous variables were used in this exploratory analysis then categorized. Potential confounding
172 factors that were identified in a previous preliminary unpublished analysis [14] were included in the

173 multivariate model for the comparison of symptomatic SARS-CoV-2 to the historical comparison
174 group. Variables identified as significantly associated in the univariable analysis were adjusted.

175


176 A sensitivity analysis was undertaken for pre-existing medical problems that might have increased the
177 risk of infection with SARS-CoV-2 or resulting morbidity (e.g., diabetes) to explore if any were
178 independently associated with the outcome. In this national observational study, the study sample
179 size was governed by the disease incidence, thus no formal power calculation was carried out. The
180 most recently available (2018) national maternity data for the constituent countries of the United
181 Kingdom was used as the denominator to estimate the incidence of hospitalization with confirmed
182 SARS-CoV-2 infection in pregnancy.

183

184 **RESULTS**

185 Between 1st March 2020 and 31st August 2020 there was a total of 1148 hospitalized women with
186 confirmed SARS-CoV-2 infection in pregnancy in the UK, approximately two thirds of whom were
187 symptomatic (n=722, 63%). There were an estimated 364,830 maternities during this period, giving
188 an overall incidence of confirmed SARS-CoV-2 in women hospitalized in pregnancy of 3.1 per 1000
189 maternities (95% CI 3.0-3.3), an incidence of symptomatic SARS-CoV-2 of 2.0 per 1000 maternities
190 (95% CI 1.9-2.2) and an incidence of asymptomatic SAR-CoV-2 of 1.2 per 1000 maternities (95% CI 1.1-
191 1.4). Most cases were in the first month of the pandemic as shown in Figure 1, which also
192 demonstrates the greater proportion of symptomatic compared to asymptomatic cases at this time.
193 The majority (99%, n=1136) had SARS-CoV-2 confirmed on laboratory testing and 12 symptomatic
194 women (1%) were diagnosed on imaging alone.

195



196

197 **Figure 1: Number of pregnant women admitted to hospital with symptomatic and asymptomatic**
 198 **confirmed SARS-CoV-2 infection in the UK between 1st March and 31st August 2020**

199

200 The most common time of diagnosis was during the third trimester (n=355, 50% of symptomatic
 201 women and n=211, 50% of asymptomatic women). The primary reason for hospital admission was
 202 known in 177 of 291 women admitted after universal screening was recommended. The most
 203 common reason for asymptomatic women to be admitted to hospital was to give birth (68%, n=78),
 204 whereas the primary reason that symptomatic women were admitted to hospital during the same
 205 period was equally spread between admission for SARS-CoV-2, to give birth, and for other reasons
 206 (30%, n=19, 37%, n=23 and 33% n=21 respectively). In symptomatic women, the majority had
 207 experienced symptoms within two weeks of admission to hospital (n=645, 94% of 689 where date of
 208 onset was known).

209

210 Compared to the historical comparison cohort without SARS-CoV-2, those hospitalized with
 211 symptomatic SARS-CoV-2 were more likely to be overweight or obese (33% vs. 27%, adjusted OR 1.86,
 212 95% CI 1.39-2.48 and 34% vs. 23% aOR 2.07, 95% CI 1.53-2.29 respectively) (Table 1). More than half
 213 (55%, n=391) of women with symptomatic SARS-CoV-2 were from Black, Asian or Other minority

214 ethnic groups, compared with 19% (n=131) of the historical comparison cohort and the odds of
 215 admission for these groups were significantly increased (Black ethnicity aOR 6.24, 95% CI 3.93-9.90,
 216 Asian ethnicity aOR 4.36, 95% CI 3.19-5.95 and Other minority ethnicity aOR 12.95, 95% CI 4.93-34.01).
 217 Nearly a quarter of women (22%, n=156) admitted with symptomatic SARS-CoV-2 had a relevant
 218 medical comorbidity compared to 13% (n=90) of the historical comparison cohort (aOR 1.83, 95% CI
 219 1.32-2.54). In the sensitivity analysis, there was some evidence that asthma and hypertension
 220 specifically increased the risk of admission (Table S2). These risk factors were similar when comparing
 221 the overall group of women admitted to hospital with SARS-CoV-2 (both symptomatic and
 222 asymptomatic) to the historical comparison cohort of women without SARS-CoV-2 (Table S3).

223

224 **Table 1: Characteristics of pregnant women with symptomatic confirmed SARS-CoV-2 infection**
 225 **admitted to hospital in the UK compared to a historical cohort without SARS-CoV-2 infection**

Characteristic	Women with symptomatic SARS-CoV-2 (N=722)	Historical comparison cohort (N=694)	OR (95% CI)	aOR**
	Number (%) *	Number (%) *		
Age (years):				
<20	12 (2%)	18 (3%)	0.71 (0.34-1.48)	1.38 (0.57-3.35)
20-34	451 (62%)	477(69%)	1	1
≥35	258 (36%)	199 (29%)	1.37 (1.09-1.72)	1.09 (0.84-1.42)
Missing	12 (2%)	0		
Body Mass index (BMI):				
Normal	221 (32%)	337 (50%)	1	1
Overweight	237 (33%)	181 (27%)	2.00 (1.54-2.58)	1.86 (1.39-2.48)
Obese	235 (34%)	155 (23%)	2.31 (1.77-3.01)	2.07 (1.53-2.79)
Missing	27	18	-	-
Either woman or partner in paid work	574 (80%)	537 (77%)	1.13 (0.88-1.46)	Omitted
Ethnic Group				
White	318 (45%)	558 (81%)	1	1
Asian	210 (30%)	79 (11%)	4.66 (3.48-6.25)	4.36 (3.19-5.95)
Black	122 (17%)	26 (4%)	8.23 (5.28-12.85)	6.24 (3.93-9.90)
Chinese	8 (1%)	7 (1%)	2.01 (0.72-5.58)	1.93 (0.68-5.52)
Other	36 (5%)	5 (1%)	12.63 (4.91-32.52)	12.95 (4.93-34.01)
Mixed	15 (2%)	14 (2%)	1.88 (0.90-3.95)	1.72 (0.78-3.80)
Missing	13	5	-	-
Current smoking	42 (6%)	135 (20%)	0.26 (0.18-0.38)	0.42 (0.28-0.62)
Missing	35	10	-	-

Any relevant pre-existing medical problems	156 (22%)	90 (13%)	1.85 (1.39-2.46)	1.83 (1.32-2.54)
Asthma	49 (7%)	31 (4%)	1.56 (0.98-2.47)	-
Hypertension	24 (3%)	3 (<1%)	7.92 (2.37-26.42)	-
Cardiac disease	13 (2%)	10 (1%)	1.25 (0.54-2.88)	-
Diabetes	22 (3%)	7 (1%)	3.08 (1.31-7.27)	-
Multiparous	436 (60%)	420 (61%)	1.01 (0.81-1.25)	Omitted
Missing	4	0	-	-
Multiple pregnancy	12 (2%)	13 (2%)	0.89 (0.30-1.95)	Omitted
Gestational diabetes	76 (11%)	37 (5%)	2.09 (1.39-3.14)	Omitted
Gestation at diagnosis (weeks)				
<22	53 (7%)			
22-27	66 (9%)			
28-31	98 (14%)			
32-36	126 (17%)			
37 or more	131 (18%)			
Peripartum	241 (34%)			
Missing	7			

226 * Percentages of those with complete data

227 ** adjusted for ethnicity, BMI, any relevant previous medical problem, smoking

228

229 Women with asymptomatic SARS-CoV-2 on hospital admission were also more likely to be of Black or
 230 minority Asian ethnicity compared to the historical comparison cohort (Black ethnicity aOR 2.54, 95%
 231 CI 2.48-4.34, Asian ethnicity aOR 2.09, 95% CI 1.48-2.95 and Other ethnicity aOR 6.90, 95% CI 2.47-
 232 19.23) (Table 2). Women with asymptomatic SARS-CoV2 were also more likely to have gestational
 233 diabetes compared to the historical comparison cohort (aOR 1.68, 95% CI 1.02-2.74), however raised
 234 BMI and pre-existing medical co-morbidities were no longer associated (Table 2). Therefore, there
 235 were also differences between women with symptomatic SARS-CoV-2 and asymptomatic SARS-CoV-2
 236 as identified in the sub-analysis (Table S4).

237

238 **Table 2: Characteristics of pregnant women with asymptomatic confirmed SARS-CoV-2 infection**
 239 **admitted to hospital in the UK compared to a historical cohort without SARS-CoV-2 infection**

Characteristic	Women with asymptomatic SARS-CoV-2 (N=426)	Historical comparison cohort (N=694)	OR (95% CI)	aOR**
	Number (%) *	Number (%) *		
Age (years):				
<20	11 (3%)	18 (3%)	0.93 (0.43-2.00)	1.17 (0.54-2.52)

20-34	313 (73%)	477(69%)	1	1
≥35	102 (24%)	199 (29%)	0.78 (0.59-1.03)	0.70 (0.53-0.94)
Missing	1	0	-	-
Body Mass index (BMI):				
Normal	188 (46%)	337 (50%)	1	Omitted
Overweight	111 (27%)	181 (27%)	1.10 (0.82-1.48)	Omitted
Obese	110 (27%)	155 (23%)	1.27 (0.94-1.72)	Omitted
Missing	16	18	-	
Either woman or partner in paid work	323 (76%)	537 (77%)	0.92 (0.69-1.22)	Omitted
Ethnic Group				
White	276 (66%)	558 (81%)	1	1
Asian	84 (20%)	79 (11%)	2.15 (1.53-3.02)	2.09 (1.48-2.95)
Black	33 (8%)	26 (4%)	2.57 (1.50-4.38)	2.54 (1.48-4.34)
Chinese	4 (1%)	7 (1%)	1.16 (0.34-3.98)	1.24 (0.36-4.29)
Other	16 (4%)	5 (1%)	6.47 (2.35-17.84)	6.90 (2.47-19.23)
Mixed	5 (1%)	14 (2%)	0.72 (0.26-2.03)	0.76 (0.27-2.14)
Missing	8	5	-	-
Current smoking	57 (16%)	135 (20%)	0.79 (0.56-1.10)	Omitted
Missing	74	10	-	-
Any relevant pre-existing medical problems	64 (15%)	90 (13%)	1.19 (0.84-1.68)	Omitted
Asthma	28 (7%)	31 (4%)	1.50 (0.89-2.55)	-
Hypertension	2 (<1%)	3 (<1%)	1.08 (0.18-6.53)	-
Cardiac disease	8 (2%)	10 (1%)	1.31 (0.51-3.34)	-
Diabetes	6 (1%)	7 (1%)	1.40 (0.47-4.20)	-
Multiparous	239 (57%)	420 (61%)	0.86 (0.67-1.09)	Omitted
Missing	5	0		-
Multiple pregnancy	4 (1%)	13 (2%)	0.50 (0.16-1.53)	Omitted
Gestational diabetes	40 (9%)	37 (5%)	1.84 (1.16-2.92)	1.68 (1.02-2.74)
Gestation at diagnosis (weeks)				
<22	23 (5%)			
22-27	11 (3%)			
28-31	8 (2%)			
32-36	39 (9%)			
37 or more	164 (39%)			
Peripartum	180 (42%)			
Missing	1			

240 * Percentages of those with complete data

241 ** adjusted for ethnicity, age and gestational diabetes

242

243

244 There were eight deaths of hospitalized women with symptomatic SARS-CoV-2 during this period, two

245 of which were unrelated to SARS-CoV-2. This gives a maternal mortality rate of 2.2 hospitalized

246 women per 100,000 maternities (95% CI 0.9-4.3). 63 (5%) women required critical care, with four

247 (<1%) reported to have received extracorporeal membrane oxygenation (ECMO) (Table 3). In those
 248 women admitted for critical care there were five maternal deaths (8%); the majority of women
 249 admitted to critical care with SARS-CoV-2 were discharged from hospital (n=56, 92%, Table S5). Whilst
 250 most women admitted to critical care gave birth before 37 weeks of pregnancy (n=38, 64%), with 32%
 251 (n=17) being born before 32 weeks, short term infant outcomes were good with 98% (n=60) being
 252 liveborn (Table S5).

253

254 **Table 3 Pregnancy and infant outcomes for pregnant women with symptomatic confirmed SARS-**
 255 **CoV-2 infection hospitalized in the UK compared to a historical cohort without SARS-CoV-2 infection**

Characteristic	Women with symptomatic SARS-CoV-2 (N=722)	Historical comparison cohort (N=694)	OR (95% CI)	aOR (95% CI)**
	Number (%) *	Number (%) *		
Required critical care	63 (9)	1 (<1)	66.15 (9.15-478.32)	57.67 (7.80-426.70)
SARS-CoV-2 pneumonia	173 (15)	0	-	-
Pre-eclampsia	15 (2%)	8 (1)	1.82 (0.77-4.32)	1.37 (0.52-3.61)
Died	8 (1)	0	-	-
Ongoing pregnancy	36 (5)			
Missing birth information	46 (6)	0	-	
Pregnancy known completed	640 (89)	694 (100)	-	
Pregnancy loss before 24 weeks' gestation	16 (2)	2 (<1)	NC	
Mode of birth				
Pre-labor cesarean	202 (32)	124 (18)	2.94 (2.23-3.87)	2.58 (1.88-3.55)
Cesarean after labor onset	112 (18)	77(11)	2.62 (1.88-3.65)	2.62 (1.79-3.85)
Operative vaginal	75 (12)	71 (10)	1.90 (1.33 – 2.73)	2.14 (1.42-3.24)
Unassisted vaginal	233 (37)	420 (61)	1 (REF)	1 (REF)
Missing	2	0	-	
Iatrogenic preterm birth <37 weeks'	87 (14)	8 (1)	13.94 (6.70-29.01)	11.43 (5.07-25.75)
Spontaneous preterm birth <37 weeks'	27 (4)	46 (7)	0.64 (0.39-1.04)	0.57 (0.32-1.01_)
	Infant outcomes (N=634)	Infant outcomes (N=705)		

Stillbirth	5 (1)	2 (<1)	2.80 (0.54-14.48)	3.20 (0.54-19.07)
Live birth	627 (99)	703 (100)	0.36 (0.07-1.84)	0.31 (0.05-1.87)
Neonatal unit admission	121 (19)	37 (5)	3.45 (2.39-4.97)	3.08 (1.99-4.77)
Neonatal death	2 (<1)	1 (<1)	2.26 (0.20-25.00)	3.91 (0.23-67.29)
Gestation at birth (weeks)***				
22-27	6 (1)	6 (1)	1.27 (0.41-3.96)	0.70 (0.15-3.16)
28-31	24 (4)	6 (1)	5.08 (2.06-12.53)	3.98 (1.48-10.70)
32-36	90 (14)	51 (7)	2.24 (1.56-3.22)	1.87 (1.23-2.85)
37 or more	503 (81)	639 (91)	1 (REF)	1 (REF)
Missing	6	1	-	-

256 * proportion of known

257 ** adjusted for ethnicity, BMI, Any relevant previous medical problem, Smoking

258 Babies

259 ***excluding stillborn

260

261 Of the 722 women admitted to hospital with symptomatic SARS-CoV-2, 89% (n=640) had completed
 262 their pregnancy at the time of analysis (Table 3, two were missing further details and infant outcomes
 263 so were excluded from the denominator). In total, 2% (n=16) of women with symptomatic SARS-CoV-
 264 2 had a pregnancy loss prior to 24 weeks'. Nearly half of women gave birth by cesarean section (n=314,
 265 49%), with 64 (6%) being for maternal compromise secondary to SARS-CoV-2 (Table S6). This
 266 represents approximately double the risk of cesarean section for women with symptomatic SARS-CoV-
 267 2 compared to the historical comparison cohort without SARS-CoV-2 (pre-labor cesarean aOR 2.58,
 268 95% CI 1.88-3.55 and cesarean after labor onset aOR 2.72, 95% CI 1.79-3.86). Operative vaginal births
 269 were also increased (aOR 2.14, 95% CI 1.42-3.24). Only 18 women received antiviral agents, two of
 270 whom were recruited to the RECOVERY Trial [15]. The most commonly-used antiviral agent was
 271 oseltamivir (n=11, 1%). Approximately 1 in 8 symptomatic women received steroids to enhance fetal
 272 lung maturation (17%, n=120) and 1 in 5 symptomatic women had a preterm birth. The majority of
 273 preterm births were iatrogenic and the risk of a woman with symptomatic SARS-CoV-2 having an
 274 iatrogenic preterm birth was more than 10-fold higher compared to pregnant women without SARS-

275 CoV-2 (14% vs. 1% aOR 11.43, 95% CI 5.07-25.75). Whilst there was an apparently lower proportion
276 of spontaneous preterm births amongst women admitted with symptomatic SARS-CoV-2, this was not
277 statistically significantly different after adjusting for potential confounders (4% vs. 7%, aOR 0.57, 95%
278 CI 0.32-1.01, Table 3).

279

280 In comparison with women found to have asymptomatic SARS-CoV-2 on hospital admission, women
281 with symptomatic SARS-CoV-2 were more likely to have a cesarean birth (prelabor cesarean: 32% vs.
282 26%, OR 1.51, 95% CI 1.11-2.06 and cesarean after labor onset: 18% vs. 14%, OR 1.58, 95% CI 1.08-
283 2.31) (Table 4). Although the risk in the asymptomatic SARS-CoV-2 group was also increased compared
284 to the historical comparison cohort without SARS-CoV-2 (Table 5) (pre-labor cesarean 26% vs. 18%,
285 aOR 2.26, 95% CI 1.62-3.17; cesarean after labor onset 14% vs 11%, aOR 1.67, 95% CI 1.12-2.52).

286

287 **Table 4 Pregnancy and infant outcomes for symptomatic versus asymptomatic SARS-CoV-2 in**
288 **pregnant women hospitalized in the UK**

Characteristic	Women with symptomatic SARS-CoV-2 (N=722)	Women with asymptomatic SARS-CoV-2 (N=426)	OR (95% CI)
	Number (%) *	Number (%) *	
Ongoing pregnancy	36 (5)	11 (3)	-
Missing birth information	46 (6)	19 (4)	-
Pregnancy known completed	640 (89)	396 (93)	-
Pregnancy loss before 24 weeks' gestation	16 (2)	15 (3)	
Mode of birth			
Pre-labor Cesarean	202 (32)	100 (26)	1.51 (1.11 – 2.06)
Cesarean after labor onset	112 (18)	53 (14)	1.58 (1.08-2.31)
Operative vaginal	75 (12)	54 (14)	1.04 (0.69-1.55)
Unassisted vaginal	233 (37)	174 (46)	1 (REF)
Missing	2	0	-
Infant outcomes			
	Infant outcomes (N=634)	Infant outcomes (N=385)	
Stillbirth	5 (1)	4 (1)	0.76 (0.20-2.85)
Live birth	627 (99)	381 (99)	-
Neonatal unit admission	121 (19)	35 (9)	1.93 (1.34-2.78)
Neonatal death	2 (<1)	2 (1)	0.61 (0.08-4.32)

Gestation at birth (weeks)*			
22-27	6 (1)	3 (1)	1.37 (0.34 – 5.51)
28-31	24 (4)	1 (<1)	16.4 (2.21-121.89)
32-36	90 (14)	32 (8)	1.92 (1.26-2.95)
37 or more	503 (81)	344 (91)	1
Median (IQR)	39 (37-40)	39 (39-40)	-
Missing	6	1	

289 * excluding stillborn babies

290 **Table 5 Pregnancy and infant outcomes for pregnant women with asymptomatic confirmed SARS-**
291 **CoV-2 infection hospitalized in the UK compared to a historical cohort without SARS-CoV-2 infection**

Characteristic	Women with asymptomatic SARS-CoV-2 (N=426)	Historical comparison cohort (N=694)	OR (95% CI)	aOR (95% CI)**
	Number (%) *	Number (%) *		
Pre-eclampsia	5 (1)	8 (1)	1.02 (0.33-3.13)	0.73 (0.21-2.52)
Ongoing pregnancy	11 (3)	0	-	
Missing birth information	19 (4)	0	-	
Pregnancy known completed	396 (93)	694 (100)	-	-
Pregnancy loss before 24 weeks' gestation	15 (3)	2 (<1)	NC	
Mode of birth				
Pre-labor cesarean	100 (26)	124 (18)	1.95 (1.32-2.67)	2.26 (1.62-3.17)
Cesarean after labor onset	53 (14)	77(11)	1.66 (1.12-2.46)	1.67 (1.12-2.52)
Operative vaginal	54 (14)	71 (10)	1.84 (1.24-2.73)	2.09 (1.38-3.16)
Unassisted vaginal	174 (46)	420 (61)	1	1
Missing	0	0	-	
	Infant outcomes (N=385)	Infant outcomes (N=705)		
Stillbirth	4 (1)	2 (<1)	3.69 (0.67-20.21)	3.63 (0.64-20.63)
Live birth	381 (99)	703 (100)	0.27 (0.05-1.49)	0.28 (0.05-1.57)
Neonatal unit admission	35 (9)	37 (5)	1.82 (1.12-2.94)	1.84 (1.12-3.03)
Neonatal death	2 (1)	1 (<1)	3.73 (0.34-41.26)	6.52 (0.58-73.13)
Gestation at birth (weeks)***				
22-27	3 (1)	6 (1)	0.93 (0.23-3.74)	0.92 (0.18-4.64)
28-31	1 (<1)	6 (1)	0.31 (0.04-2.58)	0.35 (0.04-2.99)
32-36	32 (8)	51 (7)	1.17 (0.74-1.85)	1.30 (0.91-2.08)
37 or more	344 (91)	639 (91)	1	1
Missing	1	1	-	-

292 * Percentages of those with complete data

293 ** adjusted for ethnicity, age and gestational diabetes

294 ***excluding stillborn babies

295

296 Of the 634 infants born to mothers with symptomatic SARS-CoV-2, 627 (99%) were liveborn, 81%
297 (n=503) at term (Table 3). There were seven perinatal deaths in this group; five babies were stillborn
298 and two died in the neonatal period, none of whom had confirmed SARS-CoV-2. This represents a
299 perinatal mortality rate of 11 per 1000 births amongst hospitalized women with symptomatic SARS-
300 CoV-2 (95% CI 4-23 per 1000). A total of 121 infants (19%) born to mothers with symptomatic SARS-
301 CoV-2 were admitted to a neonatal unit compared to 5% (n=37) of infants in the historical comparison
302 cohort (aOR 3.08, 95% CI 1.99-4.77). Infants born to hospitalized mothers with symptomatic SARS-
303 CoV-2 were more likely to be born at less than 37 weeks' and less than 32 weeks' of gestation
304 compared to babies born to the historical comparison cohort of mothers without SARS-CoV-2 (aOR
305 1.87, 95% CI 1.23-2.85 and aOR 3.98, 95% CI 1.48-10.70 respectively) (Table 3). Infant outcomes were
306 similar when comparing the overall group of women admitted to hospital with SARS-CoV-2 (both
307 symptomatic and asymptomatic) to women without SARS-CoV2 (Table S7).

308

309 More than one in four women that were symptomatic with SARS-CoV-2 were discharged prior to
310 giving birth and have now completed their pregnancy (n=206, 29%). In this group the majority went
311 on to have liveborn infants (n=204, 99%), at term (n=186, 90% vs n=314, 72% of those that gave birth
312 at the time of admission) with a lower proportion requiring neonatal unit admission compared to
313 those that were born at the time of admission (n=17, 8% vs. n=99, 23%).

314

315 There was no significant difference in the risk of stillbirth or neonatal death based on symptom status
316 or in asymptomatic SARS-CoV-2 compared to the historical comparison cohort. The risk of infant
317 admission to a neonatal unit was more than doubled in symptomatic compared to asymptomatic
318 women with SARS-CoV-2 on hospital admission (19% vs 9%; OR 1.93, 95% CI 1.34-2.78, Table 4).
319 Although the risk of neonatal unit admission was still increased when comparing women with
320 asymptomatic SARS-CoV-2 to the historical comparison cohort (9% vs. 5%, aOR 1.84, 95% CI 1.12-3.03,

321 Table 5). During this study period, universal screening was recommended for all babies born to
322 mothers with confirmed SARS-CoV-2 that were admitted to neonatal units for specialist care from
323 April 27th 2020. Babies born to mothers with SARS-CoV-2 that were not admitted to neonatal units
324 were not routinely tested. Only 2% (n=23) of infants tested positive for SARS-CoV-2 RNA, 12 within
325 the first 12 hours of life. Five of the infants reported to have a positive test within 12 hours were
326 admitted to a neonatal unit; only 2 of these infants had confirmed infection on re-testing. Babies born
327 to women symptomatic of SARS-CoV-2 were more likely to be preterm compared to those born to
328 asymptomatic women (19% vs 9%, aOR 1.88, 95% CI 1.20-2.95, Table 4), whose risk was not increased
329 compared to the historical comparison cohort without SARS-CoV-2 (9% vs. 9%; aOR 1.17, 95% CI 0.75-
330 1.83, Table 5).

331

332 **DISCUSSION**

333 This national prospective cohort study has reported an incidence of symptomatic SARS-CoV-2 in
334 women hospitalized in pregnancy of 2.0 per 1000 maternities (95% CI 1.9-2.2) and an incidence of
335 asymptomatic SAR-CoV-2 in women hospitalized in pregnancy of 1.2 per 1000 maternities (95% CI 1.1-
336 1.4). Compared to hospitalized pregnant women without SARS-CoV-2, hospitalized women with
337 symptomatic SARS-CoV-2 were more likely to be overweight or obese, to be of Black, Asian or Other
338 minority ethnic group, and to have a relevant medical comorbidity including asthma and hypertension.
339 The characteristics associated with asymptomatic SARS-CoV2 on hospital admission were Black, Asian
340 or Other minority ethnicity and gestational diabetes. Hospitalized pregnant women with symptomatic
341 SARS-CoV-2 were more likely to be admitted to intensive care. They were more likely to have a
342 cesarean or an operative vaginal birth, regardless of their symptom status, although the risk was
343 greatest in those symptomatic for SARS-CoV-2. Hospitalized women with SARS-CoV-2 were more likely
344 to have a preterm birth. This was driven by increased iatrogenic birth in women that were
345 symptomatic of SARS-CoV-2, as risk of preterm birth in asymptomatic women was not increased.
346 Babies born to women with SARS-CoV-2 were more likely to be admitted to a neonatal unit, regardless

347 of the mother's symptom status. There was no significant increase in stillbirth and neonatal deaths in
348 hospitalized pregnant women with SARS-CoV-2 compared to those without SARS-CoV-2, or between
349 those with symptoms and those that were asymptomatic but numbers in these groups were small.

350

351 This established method of nationwide, prospective case identification allowed rapid inception of
352 reporting of population-based data, which has added an unbiased confirmation to existing reports of
353 the characteristics and outcomes for SARS-CoV-2 in women hospitalized in pregnancy. As UKOSS is
354 the only national research platform for obstetrics in the UK, all other reports on this outcome during
355 this time frame will be a subset of these data, including our initial publication of the first six weeks of
356 the pandemic [3]. The comparison to a historical unexposed group without SARS-CoV-2 allowed
357 conclusions to be drawn about the characteristics associated with hospitalization. However, we were
358 unable to evaluate the outcomes in women with mild symptoms who were not admitted to hospital,
359 nor the incidence and outcomes of asymptomatic infection in pregnant women not presenting to
360 hospital for another cause. This study was undertaken in a high resource setting with universal health
361 care at the point of access, therefore results are generalizable to similar settings.

362

363 The sub-analysis of women by symptom status is a strength of this study. We have shown that since
364 universal testing was recommended nationally, 64% of women admitted to hospital with confirmed
365 SARS-CoV-2 were asymptomatic. To the best of our knowledge this is the first population-based study
366 to report on symptom status in pregnancy. This analysis is important because women requiring
367 hospital admission are by nature more likely to be at increased risk of adverse pregnancy outcome.
368 For example, 3% (n=31) of hospitalized pregnant women with SARS-CoV-2 had a pregnancy loss
369 compared to <1% (n=2) of those without SARS-CoV-2, but this could be a result of increased testing
370 on admission in women presenting to hospital with symptoms of pregnancy loss as opposed to an
371 effect of SARS-CoV-2 itself. This is supported by the finding of similar proportions of women with
372 pregnancy loss in the sub-analysis by symptom status. The small increase in the proportion of

373 stillbirths in women with SARS-CoV-2 compared to those without SARS-CoV-2 may also be a result of
374 this measurement bias. However, it is a limitation that despite national guidance, practice around
375 initiation of universal screening will have varied between hospitals depending on testing capacity with
376 some initiating screening earlier or later than recommended. This will have influenced the proportion
377 of asymptomatic women detected throughout this study.

378

379 We have confirmed that pregnant women hospitalized with SARS-CoV-2 were more likely to be Black,
380 Asian or Other minority ethnicity, irrespective of symptom status, age, BMI and medical comorbidities.
381 In the non-pregnant population, a recent systematic review has demonstrated that Black and Asian
382 ethnic groups are more likely to be infected with SARS-CoV-2 compared to those of White ethnicity
383 [16]. This suggests that the disproportionate impact could be attributable to increased infection in
384 these ethnic groups. However, disparities in maternal mortality between ethnic groups are well known
385 [12] and likely a result of complex interrelated factors, which may also be important in explaining the
386 increased risk of SARS-CoV-2. For example, individuals from ethnic minority backgrounds are more
387 likely to live in larger household sizes[17], be of lower socioeconomic status [18], be employed as a
388 public-facing key worker or less able to work from home [19]. Further research is required to
389 determine the reasons for this disparity in the risk of hospitalization with SARS-CoV-2 and how to
390 mitigate the risk through the care we provide. Women at increased risk should be informed of when
391 and how to seek care and clinicians should use a lower threshold for investigation and management
392 [20].

393

394 Whilst we have demonstrated that the absolute risk of poor maternal outcome in hospitalized women
395 with SARS-CoV-2 between 1st March and 31st August was low, data from the intensive care national
396 audit and research centre (ICNARC) suggest that the proportion of women admitted to intensive care
397 that are currently or recently pregnant may be increasing [21]. The reason for the increasing
398 proportion of severe SARS-CoV-2 in pregnancy compared to the general population is not known and

399 further research is required. In this study we have identified that very few pregnant women (2%) were
400 treated with anti-viral medications, much lower than in some other high resource countries such as
401 Italy where nearly a quarter of women (23%) received treatment with anti-viral agents [22]. Evidence
402 about pharmacological management in the general population is improving [15]. We have identified
403 risk factors that increase the likelihood of hospitalization and symptoms of SARS-CoV-2 and therefore
404 potentially identify those who women may benefit most from evidence-based treatment. The RCOG
405 recommends that clinicians should consider the use of medications which have been shown to be
406 beneficial and that pregnant women should be offered inclusion in trials of therapy to reduce the
407 severity of SARS-CoV-2 [20].

408

409 We have demonstrated that hospitalization with SARS-CoV-2 is associated with increased risk of
410 cesarean section, irrespective of symptom status. This supports recent systematic reviews, which have
411 reported up to 60% of pregnant women with SARS-CoV-2 had a cesarean birth [2, 23]. We also provide
412 clear data on the indication for interventional birth, the majority of which were unrelated to SARS-
413 CoV-2. The finding that cesareans are increased irrespective of symptom status suggests that some of
414 the overall increased risk is a result of measurement bias, as women with pregnancy complications
415 requiring cesarean birth are more likely to present to hospital and be screened and delivered than the
416 comparison population. However, changes in maternity practice may also contribute to this increase
417 and this warrants further investigation, as it has implications for informed decision-making, future
418 pregnancies and resource availability in both high and low-income settings.

419

420 Nearly one in five (n=120) infants of hospitalized mothers with SARS-CoV2 were born preterm and the
421 majority of these preterm infants required neonatal care (n=98, 63%). However, this was driven by
422 iatrogenic preterm birth and there was a suggestion that spontaneous preterm birth was reduced. A
423 number of other studies undertaken in high-resource settings have also reported a significant
424 reduction in preterm births and hypothesized that this was due to beneficial effects of the pandemic

425 control measures such as handwashing and social distancing reducing infections, reduced air pollution
426 and greater physical rest [24, 25]. Further research is required to determine the impact of social and
427 behavioral changes in differing risk groups and their impact on maternity outcomes in this pandemic.
428 Additionally, the high rates of iatrogenic preterm birth and neonatal unit admission due to prematurity
429 continue to suggest that the indirect effects of SARS-CoV-2 on delivery of maternity care are important
430 and will continue to be so, especially in the absence of vaccine use in pregnant women [26]. Our data
431 suggest that clinicians should be reassured that women with mild SARS-CoV-2 can be discharged from
432 hospital to continue their pregnancy safely.

433

434 **Conclusion**

435 This national study has demonstrated that raised BMI, Black, Asian or Other minority ethnicity and
436 relevant medical co-morbidities are associated with hospitalization with symptomatic SARS-CoV-2.
437 These groups should be considered for inclusion and prioritization when testing SARS-CoV-2 vaccine
438 efficacy and safety. Risks could be minimized where possible through pre-pregnancy optimization of
439 weight and medical co-morbidities. Further research is required to determine why women of Black,
440 Asian and Other minority ethnicity are disproportionately affected and how to minimize the impact of
441 this through care provision. Overall, just under one in 10 women admitted to hospital with symptoms
442 of SARS-CoV-2 in pregnancy required critical care. Outcomes in this group are predominantly good,
443 but women should be treated with medications known to be effective, to ensure their outcomes
444 improve in line with the general population. The proportion of cesarean births and iatrogenic preterm
445 birth is high which provides clear evidence of the indirect impact of SARS-CoV-2 on maternity care in
446 a high-income setting. This needs to be taken into account in guidance as the pandemic continues and
447 as SARS-CoV-2 moves to become an endemic infection, in order to prevent immediate complications
448 such as neonatal prematurity and long-term complications associated with over-intervention in care.

449

450 **Funding**

451 The study was funded by the National Institute for Health Research HS&DR Programme (project
452 number 11/46/12). MK is an NIHR Senior Investigator. The views expressed are those of the authors
453 and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

454

455 **Competing Interests**

456 MK, MQ, PB, PO'B, JJK received grants from the NIHR in relation to the submitted work. KB, NV, NS,
457 CG have no conflicts of interest to declare. EM is Trustee of RCOG, British Menopause Society and
458 Newly Chair of the Board of Trustees Group B Strep Support.

459

460 **References**

- 461 1. World Health Organisation. Rolling updates on coronavirus disease (COVID-19)
462 Geneva, Switzerland: World Health Organisation; 2020 [cited 2020 01/04/2020]. Available
463 from: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
464 [happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen).
- 465 2. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical
466 manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease
467 2019 in pregnancy: living systematic review and meta-analysis. *BMJ (Clinical research ed)*.
468 2020;370:m3320-m. doi: 10.1136/bmj.m3320. PubMed PMID: 32873575.
- 469 3. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and
470 outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in
471 UK: national population based cohort study. *BMJ (Clinical research ed)*. 2020;369:m2107-m.
472 doi: 10.1136/bmj.m2107. PubMed PMID: 32513659.
- 473 4. Royal College of Obstetricians and Gynaecologists. Principles for the testing and triage
474 of women seeking maternity care in hospital settings, during the COVID-19 pandemic; A
475 supplementary framework for maternity healthcare professionals. Royal College of
476 Obstetricians and Gynaecologists 2020.
- 477 5. Abey Suriya S, Wasif S, Counihan C, Shah N, Iliodromiti S, Cutino-Moguel M-T, et al.
478 Universal screening for SARS-CoV-2 in pregnant women at term admitted to an East London
479 maternity unit. *European journal of obstetrics, gynecology, and reproductive biology*.
480 2020;252:444-6. Epub 2020/07/22. doi: 10.1016/j.ejogrb.2020.07.035. PubMed PMID:
481 32731057.
- 482 6. Mayor S. Covid-19: Nine in 10 pregnant women with infection when admitted for
483 delivery are asymptomatic, small study finds. *BMJ*. 2020;369:m1485. doi:
484 10.1136/bmj.m1485.
- 485 7. Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, et al.
486 Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in
487 New York City: a prospective cohort study. *BJOG: An International Journal of Obstetrics &*
488 *Gynaecology*. 2020;127(12):1548-56. doi: <https://doi.org/10.1111/1471-0528.16403>.

- 489 8. Fassett MJ, Lurvey LD, Yasumura L, Nguyen M, Colli JJ, Volodarskiy M, et al. Universal
490 SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care
491 Organization. American journal of perinatology. 2020;37(11):1110-4. Epub 03.07.2020. doi:
492 10.1055/s-0040-1714060.
- 493 9. Knight M, Kurinczuk JJ, Tuffnell D, Brocklehurst P. The UK Obstetric Surveillance
494 System for rare disorders of pregnancy. BJOG. 2005;112(3):263-5. doi: 10.1111/j.1471-
495 0528.2005.00609.x. PubMed PMID: 15713136.
- 496 10. National Institute for Health Research. Urgent Public Health Research Studies for
497 COVID-19 London: National Institute for Health Research; 2020 [cited 2020 08/04/2020].
498 Available from: <https://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19.htm>.
499
- 500 11. National Health Service. Who's at higher risk from coronavirus: National Health
501 Service; 2020 [cited 2020 24th November]. Available from:
502 [https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-](https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/)
503 [higher-risk-from-coronavirus/](https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/).
- 504 12. Knight M BK, Tuffnell D, Jayakody H, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ
505 (Eds.) on behalf of MBRRACE-UK,. Saving Lives, Improving Mothers' Care - Lessons learned to
506 inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths
507 and Morbidity 2014-16. . University of Oxford: 2018.
- 508 13. UK Obstetric Surveillance System. Seasonal Influenza in Pregnancy 2016 [cited 2020
509 06/04/2020]. Available from: <https://www.npeu.ox.ac.uk/ukoss/current-surveillance/flu>.
- 510 14. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and
511 outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a
512 national cohort study using the UK Obstetric Surveillance System (UKOSS). medRxiv.
513 2020:2020.05.08.20089268. doi: 10.1101/2020.05.08.20089268.
- 514 15. RECOVERY Trial. Randomised evaluation of COVID-19 therapy (Recovery) Protocol
515 Richard Doll Building, Nuffield Department of Population Health, Oxford, OX3 7LF: University
516 of Oxford,; 2020 [cited 2020 08/12/2020]. Available from:
517 <https://www.recoverytrial.net/files/recovery-protocol-v11-1-2020-11-21.pdf>.
- 518 16. Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, et al. Ethnicity and clinical
519 outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. doi:
520 10.1016/j.eclinm.2020.100630. PubMed PMID: 100630.
- 521 17. Martin CA, Jenkins DR, Minhas JS, Gray LJ, Tang J, Williams C, et al. Socio-demographic
522 heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and
523 household size: Results from an observational cohort study. EClinicalMedicine.
524 2020;25:100466. doi: <https://doi.org/10.1016/j.eclinm.2020.100466>.
- 525 18. Iacobucci G. Covid-19: Deprived areas have the highest death rates in England and
526 Wales. BMJ. 2020;369:m1810. doi: 10.1136/bmj.m1810.
- 527 19. Office for National Statistics United Kingdom Government. Coronavirus (COVID-19)
528 related deaths by occupation, England and Wales: deaths registered up to and including 20
529 April 2020. 2020 [cited 2020 30/11/2020]. Available from:
530 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofde](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregistereduptoandincluding20april2020)
531 [ath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregist](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregistereduptoandincluding20april2020)
532 [ereduptoandincluding20april2020](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronaviruscovid19relateddeathsbyoccupationenglandandwales/deathsregistereduptoandincluding20april2020)
- 533 20. Royal College of Obstetricians and Gynaecologists and Royal College of Midwives.
534 Coronavirus (COVID-19) infection in pregnancy, information for healthcare professionals.
535 London,; 2020 14 October 2020. Report No.

- 536 21. Intensive care national audit & research centre (ICNARC). ICNARC report on COVID-19
537 in critical care: England, Wales and Northern Ireland, 27 November 2020. Napier House, 24
538 High Holborn, London: ICNARC,, 2020.
- 539 22. Maraschini A, Corsi E, Salvatore MA, Donati S. Coronavirus and birth in Italy: results of
540 a national population-based cohort study. *Ann Ist Super Sanita*. 2020;56(3):378-89. Epub
541 2020/09/23. doi: 10.4415/ann_20_03_17. PubMed PMID: 32959805.
- 542 23. Khalil A, Kalafat E, Benlioglu C, O'Brien P, Morris E, Draycott T, et al. SARS-CoV-2
543 infection in pregnancy: A systematic review and meta-analysis of clinical features and
544 pregnancy outcomes. *EClinicalMedicine*. 2020;25. doi: 10.1016/j.eclinm.2020.100446.
545 PubMed PMID: 100446.
- 546 24. Philip RK, Purtill H, Reidy E, Daly M, Imcha M, McGrath D, et al. Unprecedented
547 reduction in births of very low birthweight (VLBW) and extremely low birthweight (ELBW)
548 infants during the COVID-19 lockdown in Ireland: a 'natural experiment' allowing analysis of
549 data from the prior two decades. *BMJ Global Health*. 2020;5(9):e003075. doi: 10.1136/bmjgh-
550 2020-003075.
- 551 25. Been JV, Burgos Ochoa L, Bertens LCM, Schoenmakers S, Steegers EAP, Reiss IKM.
552 Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-
553 experimental study. *The Lancet Public Health*. 2020;5(11):e604-e11. doi: 10.1016/S2468-
554 2667(20)30223-1.
- 555 26. Knight M, Morris RK, Furniss J, Chappell LC. Include pregnant women in research—
556 particularly covid-19 research. *BMJ*. 2020;370:m3305. doi: 10.1136/bmj.m3305.
557
- 558
- 559
- 560
- 561

562 **Supporting Information Captions**

563 **Table S1: Relevant comorbidities**

Any Relevant Comorbidity
Conditions on current NHS shielding patient list <ul style="list-style-type: none">• Solid organ transplant recipient on long term immune suppression treatment• Cancers with active chemotherapy or immunosuppressive treatments /Blood/bone marrow cancer at any treatment stage• Immunosuppression sufficiently increasing infection risk• Severe respiratory disease e.g., Severe asthma (≥ 3 prescribed courses of steroids in preceding 12 months)• Rare diseases or inborn errors of metabolism e.g., Homozygous sickle cell disease• Significant heart disease
Conditions moderately associated with increased risk of complications as per current NHS guidance <ul style="list-style-type: none">• Chronic, non-severe respiratory disease e.g., Asthma• Chronic kidney disease (CKD)• Chronic cardiac disease• Chronic liver disease e.g., Chronic infective hepatitis• Chronic neurological conditions: Epilepsy• Diabetes mellitus: Type1 or Type2• Conditions or treatments that predispose to infection (e.g., steroid treatment): e.g., Systemic lupus erythematosus, Inflammatory bowel disease
Other medical conditions that investigators hypothesized could elevate risk <ul style="list-style-type: none">• Osteoporosis• Cardiac disease e.g., Arrhythmias• Treated hypertension• Hyperthyroidism• Cirrhosis (if not above, e.g., non-alcoholic fatty liver disease)• Malabsorption e.g., Coeliac disease or Peptic ulcer (gastric or duodenal)• Severe mental illness: e.g., Bipolar affective disorder, Psychosis, Schizophrenia or schizoaffective disorder• HIV infection• History of venous thromboembolism• Tuberculosis

564

565

566

567

568

569

570 **Table S2: Sensitivity analysis for pre-existing medical comorbidities in women with symptomatic**
571 **SARS-CoV-2 infection**
572

	Women with symptomatic SARS-CoV-2 (N=1148)	Historical comparison cohort (N=694)	OR (95% CI)	aOR*
Any relevant pre-existing medical problems	156 (22%)	90 (13%)	1.85 (1.39-2.46)	1.83 (1.32-2.54)
Asthma	49 (7%)	31 (4%)	1.56 (0.98-2.47)	2.12 (1.25-3.58)
Hypertension	24 (3%)	3 (<1%)	7.92 (2.37-26.42)	3.63 (0.99-13.30)
Cardiac disease	13 (2%)	10 (1%)	1.25 (0.54-2.88)	1.47 (0.59-3.63)
Diabetes	22 (3%)	7 (1%)	3.08 (1.31-7.27)	1.34 (0.48-3.68)
Liver Conditions	12 (1%)	5 (1%)	1.46 (0.51-4.15)	1.29 (0.35-4.72)
Renal Conditions	9 (1%)	5 (1%)	1.08 (0.36-3.26)	1.16 (0.28-4.80)

573
574 ***Adjusted for ethnicity, BMI, smoking, woman's age**
575

576 **Table S3: Characteristics of pregnant women with confirmed SARS-CoV-2 infection admitted to**
577 **hospital in the UK compared to a historical cohort without SARS-CoV-2**

Characteristic	Women with SARS-CoV-2 (N=1148)	Historical comparison cohort (N=694)	OR (95% CI)	aOR**
	Number (%) *	Number (%) *		
Age (years):				
<20	23 (2%)	18 (3%)	0.80 (0.43 – 1.49)	1.37 (0.67-2.78)
20-34	764(67%)	477(69%)	1 (base)	1
≥35	360 (31%)	199 (29%)	1.13 (0.92-1.39)	0.94 (0.74-1.19)
Missing	1	0	-	-
Body Mass index (BMI):				
Normal	409 (37%)	337 (50%)	1	1
Overweight	348 (31%)	181 (27%)	1.58 (1.26-1.99)	1.52 (1.18-1.95)
Obese	345 (31%)	155 (23%)	1.83 (1.45 - 2.33)	1.75 (1.33-2.27)
Missing	43	18	-	-
Either woman or partner in paid work	897 (78%)	537 (77%)	1.04 (0.84 – 1.31)	Omitted
Ethnic Group				
White	594 (53%)	558 (81%)	1	1
Asian	294 (26%)	79 (11%)	3.50 (2.66-4.60)	3.38 (2.53-4.52)
Black	155 (14%)	26 (4%)	5.60 (3.64 – 8.62)	4.81 (3.09-7.49)
Chinese	12 (1%)	7 (1%)	1.61 (0.63– 4.11)	1.59 (0.60-4.18)
Other	52 (5%)	5 (1%)	9.77 (3.87-24.64)	9.85 (3.85-25.15)
Mixed	20 (2%)	14 (2%)	1.34 (0.67-2.68)	1.36 (0.66-2.81)
Missing	21	5		
Current smoking	99 (10%)	135 (20%)	0.43 (0.32-0.57)	0.58 (0.43-0.79)
Missing	109	10		
Any relevant pre-existing medical problems	220 (19%)	90 (13%)	1.59 (1.22-2.08)	1.64 (1.22-2.20)

Asthma	77 (7%)	31 (4%)	1.54 (1.00-2.36)	-
Hypertension	26 (2%)	3 (<1%)	5.33 (1.61 - 17.70)	-
Cardiac disease	21 (2%)	10 (1%)	1.27 (0.60-2.72)	-
Diabetes	28 (2%)	7 (1%)	2.45 (1.07-5.65)	-
Multiparous	675 (59%)	420 (61%)	0.95 (0.78-1.15)	Omitted
Missing	9	0		-
Multiple pregnancy	16 (1%)	13 (2%)	0.74 (0.35-1.55)	Omitted
Gestational diabetes	116 (10%)	37 (5%)	2.00 (1.36-2.93)	Omitted
Gestation at diagnosis (weeks)				
<22	60 (5%)			
22-27	74 (6%)			
28-31	106 (9%)			
32-36	166(15%)			
37 or more	295 (26%)			
Peripartum	438 (38%)			
Missing	6			

578 * Percentages of those with complete data

579 ** adjusted for ethnicity, BMI, Any previous medical problem, Smoking

580

581 **Table S4: Characteristics of pregnant women with symptomatic versus asymptomatic SARS-CoV-2**
582 **hospitalized in the UK**

583

Characteristic	Women with symptomatic SARS-CoV-2 (N=722)	Women with asymptomatic SARS-CoV-2 (N=426)	OR (95% CI)	aOR**
	Number (%) *	Number (%) *		
Age (years):				
<20	12 (2%)	11 (3%)	0.76 (0.33-1.74)	1.02 (0.40-2.65)
20-34	451 (62%)	313 (74%)	1	1
≥35	258 (36%)	102 (24%)	1.75 (1.34-2.30)	1.62 (1.18-2.22)
Missing	1	0	-	-
Body Mass index (BMI):			1.05 (1.03-1.07)	
Normal	221 (32%)	188 (46%)	1	1
Overweight	237 (34%)	111 (27%)	1.82 (1.35-2.45)	1.66 (1.19-2.31)
Obese	235 (34%)	110 (27%)	1.82 (1.35-2.45)	1.72 (1.22-2.41)
Missing	27	16	-	-
Either woman or partner in paid work	574 (80%)	323 (76%)	1.24 (0.93-1.65)	Omitted
Ethnic Group				
White	318 (44%)	276 (65%)	1	1
Asian	208 (30%)	84 (20%)	2.17 (1.61-2.93)	2.22 (1.58-3.12)
Black	122 (17%)	33 (8%)	3.20 (2.11-4.87)	2.45 (1.55-3.87)
Chinese	8 (1%)	4 (1%)	1.74 (0.52-5.83)	1.80 (0.46-7.02)
Other	36 (5%)	16 (4%)	1.95 (1.06-3.60)	2.19 (1.08-4.41)
Mixed	15 (2%)	5 (1%)	2.60 (0.93-7.26)	1.72 (0.58-5.02)

Missing	13	8	-	-
Current smoking	42 (6%)	57 (16%)	0.34 (0.22-0.51)	0.46 (0.29-0.72)
Missing	35	74	-	-
Any Relevant Pre-existing medical problems	156 (22%)	64 (15%)	1.56 (1.13-2.15)	1.38 (0.96-1.99)
Multiparous	436 (61%)	239 (57%)	1.18 (0.92-1.50)	Omitted
Missing	4	5	-	-
Multiple pregnancy	12 (2%)	4 (1%)	1.78 (0.57-5.56)	Omitted
Gestational diabetes	76 (11%)	40 (9%)	1.13 (0.76-1.70)	Omitted
Gestation at diagnosis (weeks)				
<22	43 (6%)	17 (4%)	-	-
22-27	67 (9%)	10 (2%)	-	-
28-31	98 (14%)	8 (2%)	-	-
32-36	127 (18%)	39 (9%)	-	-
37 or more	131 (18%)	164 (39%)	-	-
Peripartum	251 (35%)	187 (44%)	-	-
Missing	5	1	-	-

584 * Percentages of those with complete data

585 ** adjusted for ethnicity, BMI, Any previous medical problem, Smoking

586

587 **Table S5: Maternal and perinatal outcomes and diagnoses amongst women with confirmed SARS-**
588 **CoV-2 infection in pregnancy admitted to intensive care**

Maternal outcomes	Women with SARS-CoV-2 admitted to intensive care (N=63)
	Number (%)
Required ECMO	4 (6%)
SARS-CoV-2 pneumonia	47 (75%)
Died	5 (8%)
Discharged well	56 (92%)
Missing outcome information	2
Multiple pregnancy	2 (3%)
Ongoing pregnancy	3 (5%)
Pregnancy completed	60 (95%)
Pregnancy loss	1 (2%)
	Infant outcomes (N=61)
Stillbirth	1 (2%)
Live birth	60 (98%)
Neonatal death	1 (2%)
Gestation at end of pregnancy (weeks)	
22-27	5 (8%)
28-31	12 (20%)
32-36	21 (36%)
37 or more	21 (36%)
Missing	1

589

590 **Table S6: Indication for cesarean in women with confirmed symptomatic, asymptomatic SARS-CoV-**
591 **2 and a historical comparison cohort**
592

Indication for cesarean	Women with symptomatic SARS-CoV-2	Women with asymptomatic SARS-CoV-2	Historical comparison cohort
Maternal compromise due to SARS-CoV-2	64 (20)		-
Failure to progress	67 (21)	34 (22)	39 (19)
Fetal Indication	71 (23)	35 (23)	51 (25)
Maternal Request	13 (4)	6 (4)	12 (6)
Previous Cesarean	44 (14)	31 (20)	43 (21)
Other	44 (14)	31 (20)	50 (25)
Unknown	11 (10)	16 (10)	6 (3)
TOTAL	314	153	201

593

594 **Table S7: Hospital, pregnancy and infant outcomes amongst women with confirmed SARS-CoV-2**
595 **infection in pregnancy compared to a historical cohort without SARS-CoV-2 infection**

Maternal outcomes	Women with SARS-CoV-2 (N=1148)	Historical comparison cohort (N=694)	OR (95% CI)	aOR (95% CI)
	Number (%)	Number (%)		
Required critical care	63 (5%)	1 (<1%)	40.18 (5.56-290.34)	33.50 (4.57-245.38)
SARS-CoV-2 pneumonia	173 (15%)	-	-	-
Pre-eclampsia	20 (2%)	8 (1%)	1.52 (0.67-3.47)	1.15 (0.47-2.82)
Died	8 (<1%)	0	-	-
Ongoing pregnancy	47 (4%)	0	-	-
Missing birth information**	65 (6%)	0	-	-
Pregnancy known completed	1036 (90%)	694 (100%)	-	-
Pregnancy loss before 24 weeks' of gestation	31 (3%)	2 (<1%)	NC	NC
Mode of birth				
Pre-labor cesarean	302 (30%)	124 (18%)	2.51 (1.96-3.23)	2.34 (1.77-3.10)
Cesarean after labor onset	165 (16%)	77(11%)	2.21 (1.63-2.99)	2.11 (1.51-2.95)
Operative vaginal	129 (13%)	71 (10%)	1.87 (1.36-2.58)	2.14 (1.51-3.05)
Unassisted vaginal	407 (41%)	420 (61%)	1	1
Missing	2	0	-	-
Iatrogenic preterm birth <37 weeks'	105 (11)	8 (1)	10.05 (4.86-20.76)	9.70 (4.39-21.42)
Spontaneous preterm birth <37 weeks'	44 (4)	46 (7)	0.65 (0.42-0.99)	0.63 (0.38-1.02)

	Infant outcomes (N=1019)	Infant outcomes (N=705)		
Stillbirth	9 (1%)	2 (<1%)	3.13 (0.68-14.55)	2.69 (0.53-13.66)
Live birth	1008 (99%)	703 (100%)	0.32 (0.07-1.48)	0.37 (0.07-1.88)
Missing	2	0	-	-
Neonatal unit admission	156 (15%)	37 (5%)	2.70 (1.91-3.83)	2.71 (1.80-4.01)
Neonatal death	4 (<1%)	1 (<1%)	2.81 (0.31-25.2)	5.30 (0.52-54.39)
Gestation at birth (weeks)***				
22-27	9 (1%)	6 (1%)	1.13 (0.40-3.20)	0.87 (0.24-3.12)
28-31	25 (2%)	6 (1%)	3.14 (1.28-7.70)	2.61 (1.01-6.75)
32-36	122 (12%)	51 (7%)	1.80 (1.28-2.54)	1.73 (1.18-2.53)
37 or more	847 (84%)	639 (91%)	1	1
Median (IQR)	39 (38-40)	40 (38-41)	-	-
Missing	7	1	-	-

596 *Percentages of those with known infant outcome data (two women lost to follow up)

597 **EDD before 1st October and no birth outcome available

598 *** excluding stillborn babies

599 NC – not comparable due to sources of data

600

601

602